Healthcare Biz Rewind: Amarin WINS FDA Approval, Impax SETTLES With Sanofi
Vascepa, a prescription formulation comprised of fish oils and used to treat high levels of triglycerides, was developed by Amarin Corporation PLC (NASDAQ:AMRN), and received FDA approval in July. Now, the Patent Office has issued a notification of a Notice of Allowance for application for the drug, which is issued after a decision is made that a patent can be granted.
Impax Laboratories, Inc. (NASDAQ:IPXL) has resolved a lawsuit with Sanofi-aventis’ (NYSE:SNY) division Genzyme, regarding two kidney disease drugs. Sanofi has agreed to grant Impax a license to market generic versions of Renvela and Renagel by mid-March 2014 and mid-September 2014 respectively. In August Impax settled with Pfizer in regards to the bladder control treatment Detrol LA.
Biopharmaceutical firm MannKind Corporation (NASDAQ:MNKD) has filed an offering as much as $500 million of mixed securities, and the specialty pharmaceutical and medical-device producer Delcath Systems, Inc. (NASDAQ:DCTH) says it will offer up to a maximum of $100 million in common stock.
Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>